Research Article

You have full text access to this OnlineOpen article

Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib†

  1. Raman Sood1,*,
  2. Harry Carloss2,
  3. Robert Kerr3,
  4. Jose Lopez4,
  5. Martin Lee5,
  6. Mark Druck6,
  7. Ian B. Walters7,
  8. Stephen J. Noga8

Article first published online: 30 JUL 2009

DOI: 10.1002/ajh.21517

Issue

American Journal of Hematology

American Journal of Hematology

Volume 84, Issue 10, pages 657–660, October 2009

Additional Information

How to Cite

Sood, R., Carloss, H., Kerr, R., Lopez, J., Lee, M., Druck, M., Walters, I. B. and Noga, S. J. (2009), Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib. Am. J. Hematol., 84: 657–660. doi: 10.1002/ajh.21517

Author Information

  1. 1

    Raman Sood Physician PC, Dunkirk, New York

  2. 2

    Western Kentucky Hematology/Oncology Group, Paducah, Kentucky

  3. 3

    Southwest Regional Cancer Center, Austin, Texas

  4. 4

    Cancer Care Centers of South Texas, Fredericksburg, Texas

  5. 5

    Park Nicollet Cancer Center, St Louis Park, Minnesota

  6. 6

    Combined Hematology Oncology Practice of New Jersey, Jersey City, New Jersey

  7. 7

    Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts

  8. 8

    Alvin & Lois Lapidus Cancer Institute, Sinai Hospital, Baltimore, Maryland

*Raman Sood Physician PC, Dunkirk, NY

  1. †

    Conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 25 SEP 2009
  2. Article first published online: 30 JUL 2009
  3. Accepted manuscript online: 30 JUL 2009 12:00AM EST
  4. Manuscript Accepted: 28 JUL 2009
  5. Manuscript Revised: 27 JUL 2009
  6. Manuscript Received: 3 APR 2009

Funded by

  • Millennium Pharmaceuticals, Inc.
  • Johnson & Johnson Pharmaceuticals Research & Development, LLC

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (109K)

References

  • 1
    VELCADE® (Bortezomib) for Injection. Prescribing Information. Cambridge, MA: Millennium Pharmaceuticals, Inc., 2008.
  • 2
    Kane RC,Farrell AT,Sridhara R, et al. United States Food and Drug Administration approval summary: Bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 2006; 12: 2955–2960.
  • 3
    San Miguel JF,Schlag R,Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906–917.
  • 4
    Jagannath S,Barlogie B,Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165–172.
  • 5
    Richardson PG,Barlogie B,Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617.
  • 6
    Richardson PG,Sonneveld P,Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498.
  • 7
    Richardson PG,Sonneveld P,Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial. Blood 2007; 110: 3557–3560.
  • 8
    National Comprehensive Cancer Network. Guidelines accessed from NCCN website March 2009. Available at: http://www.nccn.org/professionals/ physician_gls/PDF/myeloma.pdf.
  • 9
    Orlowski RZ,Nagler A,Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression. J Clin Oncol 2007; 25: 3892–3901.
  • 10
    Richardson PG,Mitsiades C,Ghobrial I, et al. Beyond single-agent bortezomib: Combination regimens in relapsed multiple myeloma. Curr Opin Oncol 2006; 18: 598–608.
  • 11
    Ciolli S,Leoni F,Casini C, et al. Feasibility and efficacy of bortezomib re-treatment in multiple myeloma. Haematologica 2007; 92: 95; Abstract 260.
  • 12
    Conner TM,Doan QD,Walters IB, et al. An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma. Clin Lymphoma Myeloma 2008; 8: 140–145.
  • 13
    Hrusovsky I,Emmerich B,von Rohr A, et al. Bortezomib retreatment in relapsed multiple myeloma (MM): Results from a binational, multicenter retrospective study. Blood 2008: 112; Abstract 2775.
  • 14
    Rubio-Martinez A,Recasens V,Montañes MA, et al. Response to bortezomib in relapsed/refractory multiple myeloma cohort. Haematologica 2007; 92: 472; Abstract 1305.
  • 15
    Rubio-Martinez A,Recasens V,Soria B, et al. Response to re-treatment on relapse multiple myeloma patients previously treated with bortezomib. Haematologica 2008; 93: 261 (Abstract 649).
  • 16
    Wolf J,Richardson PG,Schuster M, et al. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: A multicenter case series. Clin Adv Hematol Oncol 2008; 6: 755–760.
  • 17
    Petrucci MT,Blau IW,Corradini P, et al. Efficacy and safety of re-treatment with bortezomib (Velcade®) in patients with multiple myeloma: Results from a prospective international Phase II trial. Blood 2008: 112; Abstract 3690.
  • 18
    Berenson JR,Yang HH,Vescio RA, et al. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: Updated results of a phase 1/2 study after longer follow-up. Ann Hematol 2008; 87: 623–631.
  • 19
    Chanan-Khan AA,Padmanabhan S,Miller KC, et al. Final results of a phase II study of bortezomib (Velcade) in combination with liposomal doxorubicin (Doxil) and thalidomide (VDT) demonstrate a sustained high response rates in patients (pts) with relapsed (rel) or refractory (ref) multiple myeloma. Blood 2006; 108: 1010a; Abstract 3539.
  • 20
    Ciolli S,Leoni F,Casini C, et al. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Br J Haematol 2008; 141: 814–819.
  • 21
    Friedman JF,Al-Zoubi A,Kaminski M, et al. A new model predicting at least a very good partial response in patients with multiple myeloma (MM) after 2 cycles of bortezomib-based therapy. Haematologica 2006; 91: 273; Abstract 741.
  • 22
    Palumbo A,Gay F,Bringhen S, et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol 2008; 19: 1160–1165.
  • 23
    Richardson P,Wolf J,Jakubowiak A, et al. Phase I/II results of a multicenter trial of perifosine (KRX-0401) + bortezomib in patients with relapsed or relapsed/refractory multiple myeloma who were previously relapsed from or refractory to bortezomib. Blood 2008: 112; Abstract 870.
  • 24
    Richardson PG,Jagannath S,Avigan DE, et al. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): Final results of a multicenter phase 1 trial. Blood 2006; 108: 124a; Abstract 405.
  • 25
    Richardson PG,Jagannath S,Jakubowiak A, et al. Lenalidomide, bortezomib, and dexamethasone (Len/Bz/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): Encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phase II study. Blood 2008: 112; Abstract 1742.
  • 26
    Weber DM,Jagannath S,Sobecks R, et al. Combination of vorinostat plus bortezomib for the treatment of patients with multiple myeloma who have previously received bortezomib. Blood 2008: 112; Abstract 3711.
Get PDF (109K)